TRIUMPH-5 (head-to-head vs tirzepatide, NCT06662383) and TRIUMPH-Outcomes (CV/kidney CVOT, NCT06383390) are multi-year
[5] [6] However, retatrutide remains an investigational compound and has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for any clinical use
Whether you are a researcher, healthcare professional, or simply someone trying to understand the cutting edge of metabolic science, this guide breaks down everything currently known about retatrutide vs tirzepatide from their molecular targets and clinical trial outcomes to side effect profiles and their roles in the evolving peptide research ecosystem
Of the 28 selected trials, 19 were randomized, controlled, parallel, or crossover studies
There were also significant improvements in waist circumference, HgbA1c, fasting glucose, c-reactive protein, and fasting lipid levels